These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690 [TBL] [Abstract][Full Text] [Related]
3. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. Pulukuri SM; Rao JS Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000 [TBL] [Abstract][Full Text] [Related]
4. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685 [TBL] [Abstract][Full Text] [Related]
5. Altered methylation of multiple genes in carcinogenesis of the prostate. Yamanaka M; Watanabe M; Yamada Y; Takagi A; Murata T; Takahashi H; Suzuki H; Ito H; Tsukino H; Katoh T; Sugimura Y; Shiraishi T Int J Cancer; 2003 Sep; 106(3):382-7. PubMed ID: 12845678 [TBL] [Abstract][Full Text] [Related]
6. A quantitative promoter methylation profile of prostate cancer. Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627 [TBL] [Abstract][Full Text] [Related]
7. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression. Lodygin D; Diebold J; Hermeking H Oncogene; 2004 Dec; 23(56):9034-41. PubMed ID: 15489902 [TBL] [Abstract][Full Text] [Related]
8. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation. Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146 [TBL] [Abstract][Full Text] [Related]
9. Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. Carvalho JR; Filipe L; Costa VL; Ribeiro FR; Martins AT; Teixeira MR; Jerónimo C; Henrique R Apoptosis; 2010 Aug; 15(8):956-65. PubMed ID: 20464497 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Henrique R; Jerónimo C; Teixeira MR; Hoque MO; Carvalho AL; Pais I; Ribeiro FR; Oliveira J; Lopes C; Sidransky D Mol Cancer Res; 2006 Jan; 4(1):1-8. PubMed ID: 16446401 [TBL] [Abstract][Full Text] [Related]
11. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer. Sørensen KD; Borre M; Ørntoft TF; Dyrskjøt L; Tørring N Int J Cancer; 2008 Feb; 122(3):509-19. PubMed ID: 17943724 [TBL] [Abstract][Full Text] [Related]
12. 14-3-3sigma is down-regulated in human prostate cancer. Urano T; Takahashi S; Suzuki T; Fujimura T; Fujita M; Kumagai J; Horie-Inoue K; Sasano H; Kitamura T; Ouchi Y; Inoue S Biochem Biophys Res Commun; 2004 Jul; 319(3):795-800. PubMed ID: 15184053 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers. Horie-Inoue K; Inoue S Semin Cancer Biol; 2006 Jun; 16(3):235-9. PubMed ID: 16682214 [TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score. Liu W; Gong J; Hu J; Hu T; Sun Y; Du J; Sun C; Guan M; Jiang H; Lu Y Urology; 2011 Apr; 77(4):1006.e1-7. PubMed ID: 21310466 [TBL] [Abstract][Full Text] [Related]
15. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Zeng L; Rowland RG; Lele SM; Kyprianou N Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584 [TBL] [Abstract][Full Text] [Related]
16. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. Rehman I; Cross SS; Catto JW; Leiblich A; Mukherjee A; Azzouzi AR; Leung HY; Hamdy FC Prostate; 2005 Dec; 65(4):322-30. PubMed ID: 16015609 [TBL] [Abstract][Full Text] [Related]
17. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908 [TBL] [Abstract][Full Text] [Related]
18. PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Weng J; Wang J; Hu X; Wang F; Ittmann M; Liu M Int J Cancer; 2006 Mar; 118(6):1471-80. PubMed ID: 16206286 [TBL] [Abstract][Full Text] [Related]
19. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168 [TBL] [Abstract][Full Text] [Related]
20. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells. Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]